These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26350336)

  • 1. An Overview on the Search for Schizophrenia Biomarkers.
    Hallak JE; de Paula AL; Chaves C; Bressan RA; Machado-de-Sousa JP
    CNS Neurol Disord Drug Targets; 2015; 14(8):996-1000. PubMed ID: 26350336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
    Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Children with schizophrenia: clinical picture and pharmacological treatment.
    Masi G; Mucci M; Pari C
    CNS Drugs; 2006; 20(10):841-66. PubMed ID: 16999454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
    Widschwendter CG; Fleischhacker WW
    Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiological biomarkers for drug development in schizophrenia.
    Javitt DC; Spencer KM; Thaker GK; Winterer G; Hajós M
    Nat Rev Drug Discov; 2008 Jan; 7(1):68-83. PubMed ID: 18064038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview.
    Javitt DC
    Am J Manag Care; 2014 Jun; 20(8 Suppl):S160-5. PubMed ID: 25180705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimaging biomarkers for early drug development in schizophrenia.
    Tregellas JR
    Biol Psychiatry; 2014 Jul; 76(2):111-9. PubMed ID: 24094513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Negative Symptoms in Schizophrenia - an Overview].
    Klaus F; Kaiser S; Kirschner M
    Ther Umsch; 2018 Jun; 75(1):51-56. PubMed ID: 29909762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia: a review.
    Schultz SH; North SW; Shields CG
    Am Fam Physician; 2007 Jun; 75(12):1821-9. PubMed ID: 17619525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The schizophrenia prodrome revisited: a neurodevelopmental perspective.
    Cornblatt BA; Lencz T; Smith CW; Correll CU; Auther AM; Nakayama E
    Schizophr Bull; 2003; 29(4):633-51. PubMed ID: 14989404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia.
    Koychev I; Barkus E; Ettinger U; Killcross S; Roiser JP; Wilkinson L; Deakin B
    J Psychopharmacol; 2011 Sep; 25(9):1207-25. PubMed ID: 21994315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia.
    Javanbakht A
    Med Hypotheses; 2006; 67(5):1173-84. PubMed ID: 16824690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.
    Li P; Snyder GL; Vanover KE
    Curr Top Med Chem; 2016; 16(29):3385-3403. PubMed ID: 27291902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verbal memory deficit in patients with schizophrenia: an important future target for treatment.
    Toulopoulouand T; Murray RM
    Expert Rev Neurother; 2004 Jan; 4(1):43-52. PubMed ID: 15853614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.